MBX.US MBX Biosciences, Inc. Common Stock

Healthcare Biotechnology USA Stocks
53.12 USD
Close of Nov 17, 2026
26.00 72.64
Market cap
USD 2.64B
P/E
-
P/B
5.87x
ROE
-34.7%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is MBX.US undervalued?

Graham number

The Graham number of MBX Biosciences, Inc. Common Stock cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

MBX Biosciences, Inc. Common Stock fundamental analysis

No fundamental analysis for MBX Biosciences, Inc. Common Stock yet.

MBX Biosciences, Inc. Common Stock stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About MBX Biosciences, Inc. Common Stock

MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is Canvuparatide (MBX 2109), a parathyroid hormone peptide prodrug, which is in Phase 3 clinical trial for the treatment of chronic hypoparathyroidism. The company is also developing Imapextide (MBX 1416), a long-acting glucagon-like peptide-1 (GLP-1) recep…

Full company profile